XNPT：跟随大盘的回调亦或庄家的震仓？

陈冠西

XNPT过去两周在突破20元阻力位后随大盘回落，但令人惊奇的是昨天大盘上升近120点，XNPT却以平盘做收。这使我怀疑市场普遍看好获得FDA点头通过的XNPT这总计近10%的跌幅是否真正是由大盘的原因引起的，亦或是庄家在FDA决定日前一贯的震仓伎俩？

DYAX在FDA决定日前的剧烈震荡想必很多人还记忆犹新。中小投资者们在这个时候犹如骑在一头西班牙斗牛背上，有多少能握紧手中的缰绳不被震飞出去？但有着强大神经的真正斗牛士是不会给这种阵仗吓倒的。恰恰相反，他们会视其为挑战自我的好机会。炒股的“斗牛士”自然也不会被震仓吓倒，而是把握机会低位加仓。DYAX的经验表明，坚持到最后的，终将成为市场的赢家。

XNPT现在的情型与当初DYAX的情况何其相似。如果说我们简单地认为XNPT最近是随大盘回调，那么我不得不说，现在的价位已严重超卖。但恐怕实情是有大庄家在操控股价。有留意LEVEL2股价波动的朋友或许知道，XNPT并不是人手控盘的，而是自动交易系统在控盘。从机构投资者的构成来看，极有可能来自Barclays或Morgan Stanley自动交易系统。虽然软件不是一般的先进，但做出来的TRICK还是很难逃得过老练狩猎者的眼光。

在距离FDA决定日只有一周之际，我已做好了与这头“烈牛”做战的准备：握紧手中的每一股份，并在震荡回调时把握机会加仓。狡猾的TRANSFORMER式庄家，我们2月9号见！

关于XNPT更详的信息，请看上一帖:《市场聚焦XNPT》
http://www.hutong9.com/viewthrea ... &extra=page%3D1　

*声明：本人的发布的信息都来自互联网可靠资源及个人原创，只供讨论参考，不作为任何投资理财或股票买卖的依据。股市无常，风险自负。

陈冠西

今天XNPT强力回归，是个很不错的召头，我还是坚持上一帖中$25最低目标价。

slcgh

today it is very good。

gucci320

今天大部分股都很不错 特别是药股 很多都涨个10%

babyruth

Its very possible it will run up to $25 pre-approval if broad market cooperates.

Cheers!

baicaiprince

1# 陈冠西

Thanks for sharing

kang_wang

It has a bull flag now after yesterday's breakout?

陈冠西

7# kang_wang

虽然大盘下跌，但今天XNPT继续昨天的良好势头，决定日前很大可能会在震荡中继续上升。

我的英文版本，看过觉得不错的帮忙REC一下。

http://caps.fool.com/Blogs/ViewP ... 1002601384202602665　

baicaiprince

8# 陈冠西


Just rec'ed it

CRxyz

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT - News) announced today that, subject to the approval of the U.S. Food and Drug Administration (FDA), the brand name for GSK1838262/XP13512 (gabapentin enacarbil) in the United States will be Horizant. The Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for Horizant for the treatment of moderate-to-severe primary restless legs syndrome (RLS) is February 9, 2010. Horizant is licensed to GlaxoSmithKline in the United States and several other countries.

Separately, GSK announced today that it is proposing to cease discovery research in certain neuroscience areas, including depression and pain. XP13512 is in development for the management of post-herpetic neuralgia and painful diabetic neuropathy. GSK and XenoPort are discussing the next steps in the development plan for XP13512 in the neuropathic pain area and will disclose this development plan at a future date.

babyruth

有些公司批了以后股价大涨, 象DNDN和HGSI涨十倍左右. 我估计XNPT股价会涨到30-35之间.

Vanda Pharmaceuticals (NASDAQL:VNDA) experienced an 800% increase in share price when it when the FDA granted approval for Fanapt, a drug to treat schizophrenia, back in May.

On Dec. 1, Santarus Inc. (NASDAQ:SNTS) announced its heartburn medication, Zegerid, was approved by the FCA. The Stock went up over 40% in 24 hours.

unlink

GlaxoSmithKline (GSK) Savings Plan May Hit XenoPort, Inc. (XNPT) Partnership
2/5/2010

Bookmark and Share

AP -- The future of a partnership between XenoPort Inc. and GlaxoSmithKline PLC appeared to be in doubt Thursday after Glaxo said it may end research on pain treatments. GlaxoSmithKline, one of the world's largest drugmakers, said its neuroscience researchers will focus on inflammatory and degenerative diseases and may stop research into depression and pain drugs. The proposals were part of a cost-saving plan.

babyruth

12# unlink

This news has no effect on XNPT's stock price if it gets FDA approval:

"A spokesperson for GlaxoSmithKline, Philip Thomson, tells Bloomberg that only research jobs connected to pain and depression programs would be affected"

Correct: only research, not development (although Witty's remarks initially were a bit confusing).

"Witty expects to be responsible for another six molecular entity approvals over the next 18 months."

Horizant was explicitly mentioned as one of them.

wangbin

没过！！！6。65 now

baicaiprince

Losing big

gucci320

记得有个买了1K的XNPT 还坚信FDA之前能上25的兄弟怎么样了

quickcow

风险太大！

柴禾

sandera

炒股几个月来,观察不少医药股都有这一类似特点,一个好消息或一个坏消息使股价骤变.

我只买过一支SVA.